Arbutus Biopharma (ABUS) Upgraded to “Hold” at BidaskClub

BidaskClub upgraded shares of Arbutus Biopharma (NASDAQ:ABUS) from a sell rating to a hold rating in a report issued on Thursday morning.

Several other equities research analysts also recently issued reports on ABUS. Chardan Capital reiterated a buy rating on shares of Arbutus Biopharma in a report on Wednesday, September 13th. Wedbush reiterated an outperform rating and issued a $9.00 price objective on shares of Arbutus Biopharma in a report on Wednesday, September 20th. ValuEngine upgraded Arbutus Biopharma from a sell rating to a hold rating in a report on Thursday, September 21st. JMP Securities reiterated an outperform rating and issued a $13.00 price objective (up previously from $12.00) on shares of Arbutus Biopharma in a report on Wednesday, October 4th. Finally, Leerink Swann reiterated a market perform rating and issued a $5.00 price objective (up previously from $4.00) on shares of Arbutus Biopharma in a report on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The company has a consensus rating of Hold and an average price target of $12.50.

Shares of Arbutus Biopharma (ABUS) opened at $5.55 on Thursday. The company has a quick ratio of 11.03, a current ratio of 11.03 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $305.54, a price-to-earnings ratio of -1.12 and a beta of 1.08. Arbutus Biopharma has a 1-year low of $2.35 and a 1-year high of $8.25.

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in shares of Arbutus Biopharma by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 2,035 shares during the period. OxFORD Asset Management LLP increased its holdings in Arbutus Biopharma by 89.9% during the 2nd quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock worth $300,000 after purchasing an additional 39,436 shares during the period. Victory Capital Management Inc. purchased a new stake in Arbutus Biopharma during the 2nd quarter worth about $478,000. Point72 Asset Management L.P. purchased a new stake in Arbutus Biopharma during the 3rd quarter worth about $1,393,000. Finally, RTW Investments LP increased its holdings in Arbutus Biopharma by 1.1% during the 3rd quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock worth $32,651,000 after purchasing an additional 56,457 shares during the period. Hedge funds and other institutional investors own 59.97% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Arbutus Biopharma (ABUS) Upgraded to “Hold” at BidaskClub” was published by Equities Focus and is the sole property of of Equities Focus. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.equitiesfocus.com/2018/01/08/arbutus-biopharma-abus-upgraded-to-hold-at-bidaskclub.html.

About Arbutus Biopharma

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply